Literature DB >> 23812041

Types and outcomes of cardioversion in patients admitted to hospital for atrial fibrillation: results of the German RHYTHM-AF Study.

Anselm K Gitt1, Wenefrieda Smolka, Galin Michailov, Alexandra Bernhardt, David Pittrow, Thorsten Lewalter.   

Abstract

BACKGROUND: Atrial fibrillation (AF) accounts for approximately one-third of hospitalizations for cardiac rhythm disturbances. Little is known about the characteristics of current use of cardioversion (CV) and its success rates in clinical practice in Germany.
METHODS: As part of the international RHYTHM-AF Study, 655 consecutive patients with documented AF (mean age 68.3 ± 10.5 years, 64.9 % males) who were considered candidates for CV were prospectively enrolled in 22 German hospitals (21 academic/teaching and 1 non-teaching). CV was considered successful if sinus rhythm or atrial rhythm was obtained within 1 day after start of pharmacological CV (PCV) or if sinus rhythm was achieved and maintained for at least 10 min after electrical CV (ECV).
RESULTS: Patients with AF considered for CV had ECG in 94.4 %, Holter ECG in 25.8 %, and transesophageal echocardiography (TEE) in 73.1 % of cases. They underwent ECV (after mean 16 h, range 4-48), in 65.3 % and PCV in 6.7 % of patients (amiodarone in 47.7 %, flecainide in 27.3 %, propafenone in 2.3 %) as first CV procedure. No CV was performed in 27.9 %, mainly due to spontaneous CV or pathologic TEE. Primary success rates were 86.7 % for electrical CV and 54.5 % for pharmacological CV. More patients in the ECV group compared to the PCV group received oral anticoagulation at discharge (79.2 vs. 59.1 %, p < 0.001), and at 60 days (77.5 vs. 56.8 %, p < 0.001). Further, at 60 days the proportion of patients in sinus rhythm was not different between groups (ECV 76.8 % vs. PCV 77.3 %).
CONCLUSIONS: In large academic centres in Germany, the preferred CV method is electrical, mainly due to its easy access and to its higher success rate for the initial restoration of sinus rhythm. Considering the limitations of the open-label, non-randomised study design, overall short-term success rates appeared higher after ECV compared to PCV during hospitalisation, but not after 60 days.

Entities:  

Mesh:

Year:  2013        PMID: 23812041     DOI: 10.1007/s00392-013-0586-x

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  22 in total

1.  Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation.

Authors:  Robby Nieuwlaat; Alessandro Capucci; A John Camm; S Bertil Olsson; Dietrich Andresen; D Wyn Davies; Stuart Cobbe; Günter Breithardt; Jean-Yves Le Heuzey; Martin H Prins; Samuel Lévy; Harry J G M Crijns
Journal:  Eur Heart J       Date:  2005-10-04       Impact factor: 29.983

2.  Prevalence of left atrial thrombus and dense spontaneous echo contrast in patients with short-term atrial fibrillation < 48 hours undergoing cardioversion: value of transesophageal echocardiography to guide cardioversion.

Authors:  Thomas Kleemann; Torsten Becker; Margit Strauss; Steffen Schneider; Karlheinz Seidl
Journal:  J Am Soc Echocardiogr       Date:  2009-10-31       Impact factor: 5.251

3.  A population-based study of mortality among patients with atrial fibrillation or flutter.

Authors:  Humberto Vidaillet; Juan F Granada; P o-Huang Chyou; Karen Maassen; Mario Ortiz; Juan N Pulido; Param Sharma; Peter N Smith; John Hayes
Journal:  Am J Med       Date:  2002-10-01       Impact factor: 4.965

4.  Embolic events in patients with atrial fibrillation and effective anticoagulation: value of transesophageal echocardiography to guide direct-current cardioversion. Final results of the Ludwigshafen Observational Cardioversion Study.

Authors:  Karlheinz Seidl; Monika Rameken; Axel Drögemüller; Margit Vater; Andreas Brandt; Harald Schwacke; Caroline Bergmeier; Ralf Zahn; Jochen Senges
Journal:  J Am Coll Cardiol       Date:  2002-05-01       Impact factor: 24.094

5.  Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation.

Authors:  Jeroen M L Hendriks; Rianne de Wit; Harry J G M Crijns; Hubertus J M Vrijhoef; Martin H Prins; Ron Pisters; Laurent A F G Pison; Yuri Blaauw; Robert G Tieleman
Journal:  Eur Heart J       Date:  2012-03-27       Impact factor: 29.983

6.  Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks.

Authors:  S Mittal; S Ayati; K M Stein; D Schwartzman; D Cavlovich; P J Tchou; S M Markowitz; D J Slotwiner; M A Scheiner; B B Lerman
Journal:  Circulation       Date:  2000-03-21       Impact factor: 29.690

Review 7.  Cardioversion related thromboembolism: value of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation.

Authors:  Karlheinz Seidl; Jochen Senges
Journal:  Card Electrophysiol Rev       Date:  2003-12

8.  Rising rates of hospital admissions for atrial fibrillation.

Authors:  Jens Friberg; Pernille Buch; Henrik Scharling; Niels Gadsbphioll; Gorm B Jensen
Journal:  Epidemiology       Date:  2003-11       Impact factor: 4.822

9.  Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study.

Authors:  Thomas J Wang; Martin G Larson; Daniel Levy; Ramachandran S Vasan; Eric P Leip; Philip A Wolf; Ralph B D'Agostino; Joanne M Murabito; William B Kannel; Emelia J Benjamin
Journal:  Circulation       Date:  2003-05-27       Impact factor: 29.690

10.  Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry.

Authors:  Thomas Meinertz; Wilhelm Kirch; Ludger Rosin; David Pittrow; Stefan N Willich; Paulus Kirchhof
Journal:  Clin Res Cardiol       Date:  2011-05-01       Impact factor: 5.460

View more
  10 in total

1.  Health-related quality of life changes in patients undergoing repeated catheter ablation for atrial fibrillation.

Authors:  Thomas Pezawas; Robin Ristl; Christoph Schukro; Herwig Schmidinger
Journal:  Clin Res Cardiol       Date:  2015-06-24       Impact factor: 5.460

Review 2.  Atrial fibrillation and long-term sports practice: epidemiology and mechanisms.

Authors:  S Wernhart; M Halle
Journal:  Clin Res Cardiol       Date:  2014-12-25       Impact factor: 5.460

3.  Impact of real-time contact force and impedance measurement in pulmonary vein isolation procedures for treatment of atrial fibrillation.

Authors:  Reza Wakili; Sebastian Clauss; Viola Schmidt; Michael Ulbrich; Anton Hahnefeld; Franziska Schüssler; Johannes Siebermair; Stefan Kääb; Heidi L Estner
Journal:  Clin Res Cardiol       Date:  2013-10-06       Impact factor: 5.460

4.  Efficacy and safety in pharmacological cardioversion of recent-onset atrial fibrillation: a propensity score matching to compare amiodarone vs class IC antiarrhythmic drugs.

Authors:  Antonio Bonora; Gianni Turcato; Elena Franchi; Gabriele Taioli; Alice Dilda; Germana Zerman; Antonio Maccagnani; Claudio Pistorelli; Oliviero Olivieri
Journal:  Intern Emerg Med       Date:  2016-07-06       Impact factor: 3.397

5.  Cardioversion of atrial fibrillation or atrial flutter into sinus rhythm reduces nocturnal central respiratory events and unmasks obstructive sleep apnoea.

Authors:  Henrik Fox; Thomas Bitter; Dieter Horstkotte; Olaf Oldenburg
Journal:  Clin Res Cardiol       Date:  2015-11-09       Impact factor: 5.460

6.  Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation - results from the GARFIELD-AF registry.

Authors:  Marita Knudsen Pope; Dan Atar; Arne Svilaas; Torstein Hole; Jørn Dalsgaard Nielsen; Ulrik Hintze; Milita Crisby; Pekka Raatikainen; K E Juhani Airaksinen; Saverio Virdone; Karen Pieper; Gloria Kayani; Jean-Yves Le Heuzey; Jan Steffel; Janina Stepinska; Jean-Pierre Bassand; A John Camm
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

7.  HALT & REVERSE: Hsf1 activators lower cardiomyocyt damage; towards a novel approach to REVERSE atrial fibrillation.

Authors:  Eva A H Lanters; Denise M S van Marion; Charles Kik; Herman Steen; Ad J J C Bogers; Maurits A Allessie; Bianca J J M Brundel; Natasja M S de Groot
Journal:  J Transl Med       Date:  2015-11-05       Impact factor: 5.531

Review 8.  Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches?

Authors:  Gregory Y H Lip; Sana M Al-Khatib; Francisco G Cosio; Amitava Banerjee; Irina Savelieva; Jeremy Ruskin; Dan Blendea; Stanley Nattel; Joseph De Bono; Jennifer M Conroy; Paul L Hess; Eduard Guasch; Jonathan L Halperin; Paulus Kirchhof; M Dolores G Cosio; A John Camm
Journal:  J Am Heart Assoc       Date:  2014-08-27       Impact factor: 5.501

9.  Pharmacological Cardioversion With Antazoline in Atrial Fibrillation: The Results of the CANT Study.

Authors:  Maciej T Wybraniec; Wojciech Wróbel; Katarzyna Wilkosz; Karolina Wrona; Karolina Bula; Katarzyna Mizia-Stec
Journal:  J Am Heart Assoc       Date:  2018-10-16       Impact factor: 5.501

10.  CHA2DS2-VASc score predicts atrial fibrillation recurrence after cardioversion: Systematic review and individual patient pooled meta-analysis.

Authors:  Francesco Vitali; Matteo Serenelli; Juhani Airaksinen; Rita Pavasini; Anna Tomaszuk-Kazberuk; Elzbieta Mlodawska; Samuli Jaakkola; Cristina Balla; Lorenzo Falsetti; Nicola Tarquinio; Roberto Ferrari; Angelo Squeri; Gianluca Campo; Matteo Bertini
Journal:  Clin Cardiol       Date:  2019-02-11       Impact factor: 2.882

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.